Clinical Trials Logo

Tauopathies clinical trials

View clinical trials related to Tauopathies.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05344989 Active, not recruiting - Healthy Volunteers Clinical Trials

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Start date: May 6, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human (FIH), double-blinded, placebo-controlled study where healthy subjects are randomly allocated to receive APNmAb005 or placebo. Approximately 5 dosing groups (cohorts) are planned with 8 subjects (randomized to 6 active: 2 placebo) per cohort. the starting dose of APNmAb005 is 5 mg/kg and the anticipated doses for subsequent cohorts are 10, 25, 50 and 70 mg/kg. A Safety Review Team (SRT) will review data on an ongoing basis throughout the study and before progression to the next dose level cohort. Subjects will receive a single dose of either APNmAb005 or placebo administered as a single IV infusion on Day 1 of the study and will remain in the study center until Day 3 (48 hours after dosing). They will return to the study center for 7 outpatient visits. The duration of the study, excluding screening, is approximately 71 days.

NCT ID: NCT04734379 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

ROCKIT-1
Start date: January 22, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

NCT ID: NCT02966145 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy (PSP)

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

4RTNI-2
Start date: January 2016
Phase:
Study type: Observational

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.